rectocele
发表于 2025-3-23 12:37:56
Restatement and Propositions (1968)ugh 75 % of the LSDs affect the central nervous system (CNS), the replacement enzymes are large molecules that do not cross the blood–brain barrier (BBB), and, thus, ERT is not an effective therapy for the CNS manifestations of the disease. The brain and spinal cord can be treated if the enzyme is r
PLIC
发表于 2025-3-23 16:00:11
http://reply.papertrans.cn/19/1866/186527/186527_12.png
发生
发表于 2025-3-23 18:42:18
http://reply.papertrans.cn/19/1866/186527/186527_13.png
柔声地说
发表于 2025-3-23 22:18:30
The New Synthese Historical Library protein therapeutics. However, advantage has been taken of this phenomenon for formulation of slow-release products such as the long-acting insulin analog, Lantus. or the peptidic gonadotropin-releasing hormone receptor blocker, Firmagon.. Aggregation in vivo may also take place after intravenous (
municipality
发表于 2025-3-24 04:10:16
,Die Computer in Princeton, 1946–1952,r, highly susceptible to chemical modifications that can affect their potency and predispose patients to adverse immunogenic responses. This chapter presents the common routes of hydrolytic degradation of mAbs, their effects on in vivo performance, and the various strategies used to overcome these e
胎儿
发表于 2025-3-24 09:43:01
Lebensgeschichten aus der Wissenschaft been associated with a large number of pathologies (Guttmann and Ghoshal 2011; Martinez et al. 2010; Nakamura et al. 2012) as well as biological aging (Stadtman 1988, 1992; Oliver et al. 1987). Protein oxidation can lead to changes in activity, conformation, protein–protein interactions, and half-l
坦白
发表于 2025-3-24 12:12:04
http://reply.papertrans.cn/19/1866/186527/186527_17.png
patriarch
发表于 2025-3-24 17:14:40
http://reply.papertrans.cn/19/1866/186527/186527_18.png
AGOG
发表于 2025-3-24 20:29:46
http://reply.papertrans.cn/19/1866/186527/186527_19.png
独轮车
发表于 2025-3-25 00:29:57
,The Gathering Storm – “A Shower of Fishes”,asis on recent advances in the design and manipulation of functional Ig fragments for therapeutic applications. Currently, the challenge is to create next generation types of antibodies that offer improvements over classical MAbs with regard to biomolecular attributes and clinical performance. Bispe